Praxis Precision Medicines (PRAX) director granted RSUs and stock options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Praxis Precision Medicines director Gregory Norden reported equity awards consisting of restricted stock units and stock options. He was granted 1,371 restricted stock units, each representing a contingent right to receive one share of common stock. These units vest in a single installment on the earlier of June 10, 2027 or the company’s 2027 annual stockholder meeting.

In a separate award, Norden received options to buy 648 shares of common stock at an exercise price of $240.66 per share. These options vest in twelve equal monthly installments starting on July 10, 2026, with the final installment on the earlier of June 10, 2027 or the 2027 annual meeting. Following the reported grants, he holds 1,559 common shares directly and 648 options, reflecting routine director compensation rather than open-market trading.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Norden Gregory

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	648	$0.00	--
Grant/Award	Common Stock	1,371	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 648 shares (Direct, null); Common Stock — 1,559 shares (Direct, null)

Footnotes (1)

Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

RSU grant: 1,371 units RSU vesting date: June 10, 2027 Options granted: 648 options +5 more

8 metrics

RSU grant 1,371 units Restricted stock units granted to director on June 10, 2026

RSU vesting date June 10, 2027 Vests on earlier of this date or 2027 annual meeting

Options granted 648 options Stock Option (Right to Buy) on common stock

Option exercise price $240.66 per share Conversion or exercise price for 648 options

Option expiration June 10, 2036 Expiration date of stock options

Shares after award 1,559 shares Total common shares following RSU grant

Underlying option shares 648 shares Common shares underlying the stock options

Option vesting schedule 12 monthly installments From July 10, 2026 to earlier of June 10, 2027 or 2027 meeting

Key Terms

restricted stock units, contingent right, Stock Option (Right to Buy), vest in twelve (12) equal monthly installments, +1 more

5 terms

restricted stock units financial

"Mr. Norden was awarded 1,371 restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share"

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

vest in twelve (12) equal monthly installments financial

"The shares subject to this option shall vest in twelve (12) equal monthly installments"

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 05:24 PM Accepted by SEC EDGAR 06/12/2026 - 05:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Norden Gregory

(Last)

(First)

(Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/10/2026		A⁽¹⁾		1,371	A	$0	1,559	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$240.66	06/10/2026		A		648		⁽²⁾	06/10/2036	Common Stock	648	$0	648	D

Explanation of Responses:

1. Mr. Norden was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

2. The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Remarks:

	/s/ Alex Nemiroff, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Praxis Precision Medicines (PRAX) director Gregory Norden receive in this Form 4?

Gregory Norden received equity-based compensation, including 1,371 restricted stock units and stock options for 648 shares at an exercise price of $240.66. These awards represent routine director compensation rather than open-market purchases or sales of PRAX stock.

How do Gregory Norden’s 1,371 restricted stock units at Praxis (PRAX) vest?

The 1,371 restricted stock units vest in a single installment on the earlier of June 10, 2027 or the 2027 annual stockholder meeting. Each vested unit converts into one share of Praxis Precision Medicines common stock upon settlement, delivered only in shares.

What are the key terms of Gregory Norden’s stock options reported by Praxis (PRAX)?

Norden was granted options on 648 shares of Praxis common stock with a $240.66 exercise price and expiration on June 10, 2036. The options vest in twelve equal monthly installments beginning July 10, 2026, through the earlier of June 10, 2027 or the 2027 annual meeting.

Did Gregory Norden buy or sell Praxis (PRAX) shares on the open market in this Form 4?

No open-market buy or sell occurred. The Form 4 reports acquisitions coded as grants or awards: restricted stock units and stock options. These awards are compensation-related and do not reflect discretionary market trading in Praxis Precision Medicines shares.

How many Praxis (PRAX) common shares does Gregory Norden hold after these equity grants?

After the reported transactions, Norden directly holds 1,559 Praxis common shares and stock options for 648 additional shares. The filing shows these positions as of the award date, reflecting his updated equity stake linked to director compensation.